Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Background
    • Rationale
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News Center
Learn how we approach
Regenerative Cardiac
Medicine of Tomorrow

RECARDIO’S Profile

RECARDIO (REgenerative CARDIOvascular Therapy) is a clinical-stage life science company focusing on therapies for cardiovascular, oncology and infectious diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe.

Read more

Regenerative cardiac therapy

RECARDIO’s lead drug dutogliptin, a DPP-IV inhibitor, demonstrated significant effects in activating cardiac regeneration. The clinical program presents a therapeutic platform for cardiovascular patients, with potential of improving heart function, quality of life and survival.

Read more

News / Events

Interim Analysis of Recardio’s Phase II Clinical Trial published in European Heart Journal

December 17, 2020

Study Protocol of Phase 2 Trial of Recardio Published in the Trials Journal BioMed Central

September 14, 2020

Interim Analysis of Recardio’s Phase II Clinical Trial to be Presented at the 2020 Congress of the European Society of Cardiology

June 29, 2020

Read More

Clinical Studies

RECARDIO’s global and multicenter Phase 2B study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.

Read More

Careers

Being located in the US and Europe, we are committed to develop the regenerative therapies of the future. To support our clinical development, we are continuously looking for expanding our team.

Read More

  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2021 · All Rights Reserved

Copyright © 2021 · Recardio on Genesis Framework · WordPress · Log in